CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

Michele Stanchina, Alessandro Pastore, Sean Devlin, Christopher Famulare, Eytan Stein, Justin Taylor

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.

Original languageEnglish (US)
Article number85
JournalJournal of Hematology and Oncology
Volume12
Issue number1
DOIs
StatePublished - Aug 22 2019
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Antibody-drug conjugate
  • CD33

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A'. Together they form a unique fingerprint.

Cite this